002675Dongcheng PharmaceuticalSZSE

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

东诚药业

002675

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ISINCNE100001DP5
ListedMay 25, 2012
Websitewww.dcb-group.com
IR Emailstock@dcb-group.com
Phone(+86)535-6371119
Sourcecninfo.com.cn
AddressNo. 7 Changbaishan Road, Economic and Technologic Development Zone, Yantai, Shandong

Company Overview

Yantai Dongcheng Pharmaceutical Group Co., Ltd. is a pharmaceutical manufacturing company listed on the Shenzhen Stock Exchange since 2012. The company focuses on the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms, implementing a dual strategy to promote both endogenous growth and external expansion in the biopharmaceutical sector. Yantai Dongcheng aims to enhance its core competitiveness through strategic adjustments in its product offerings and performance assessments, while also pursuing new customer and market development. The company operates primarily in three business lines: APIs, finished dosage forms, and nuclear medicine. In the API segment, Yantai Dongcheng leverages its competitive advantages in international certifications, customer resources, and quality management. The finished dosage forms business benefits from a well-established sales and marketing system, which has been developed since 2014. Additionally, the company has made significant strides in the nuclear medicine sector, with a focus on radiopharmaceuticals, establishing platforms for production, research, and distribution. This diversification positions Yantai Dongcheng for sustained growth in the pharmaceutical industry.

AI-generated from company disclosures and CNInfo data.

Company Profile

1. In API business, we have wide competitive advantages in international certification ,international permit ,customers resources, sales network, products structure, and quality management, R&D and reserves. 2. In finished dosage form business, we have the advantage of product reserves. In 2014, we began to establish a professional sales and marketing team and now we have formed a well-established sales and marketing system, including a professional attraction marketing team, an experienced government affairs team, a refined operation marketing team and a responsible sales services team. 3. In R&D, we improve the new product development capabilities through increasing R&D investment, establishing the prefect R&D system, and cooperating with the famous pharmaceutical scientific research institutes actively. 4. We successively have the radiopharmaceuticals production platform (represented by Yunke Pharmaceutical), the radiopharmaceuticals R&D platform (represented by Yitai Pharmaceutical), the radiolabelling and distribution platform -represented by Dongcheng Xinke. The company has become one of the few pharmaceutical enterprises with complete qualification and layout in the key link of radiopharmaceutical industry chains, and the radiopharmaceuticals field has become the new profit growth point of our company.

86 announcements tracked· Last: November 16, 2026

Key Financials

As of 2026-11-14T00:00:00.000+00:00
Revenue¥1.94bn
Net Profit¥163.6M
ROE3.67%
Debt Ratio41.97%
Monetary Funds¥747.8M
Receivables¥993.0M
Goodwill¥2.45bn
Total Shares824.6M

Announcements

86 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.